medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2021, Number 04

<< Back

Ginecol Obstet Mex 2021; 89 (04)

Primary choriocarcinoma of uterine cervix. Extremely rare disease, case presentation

Cantón-Romero JC, Carrillo-Garibaldi ÓJ, Juárez-López GE, Salas-González E

Language: Spanish
References: 15
Page: 350-356
PDF size: 216.41 Kb.


ABSTRACT

Background: Cervical pregnancy is an extremely rare site, with an incidence of 1 in 9000 deliveries. The association with choriocarcinoma is even rarer. The most common location of choriocarcinoma is the uterus; it can be found in the salpingeum, vagina, vulva, cervix or pelvic region. Chemotherapy is highly effective in treating patients with choriocarcinoma, with cure rates of 100% in low-risk conditions and 80 to 90% in high-risk.
Objective: To determine the extent of disease and contribute to medical knowledge of the timely diagnosis and correct multidisciplinary treatment of choriocarcinoma in an extremely rare presentation.
Clinical case: 36-year-old female patient with complete abortion at 5.4 weeks of gestation, with no evidence of intrauterine pregnancy. She was treated with vaginal misoprostol and, subsequently, contraceptives for two months. The patient continued with scant transvaginal bleeding and diffuse pelvic pain. Abdomino-pelvic axial tomography showed a 15 cm tumor in the uterus at the level of the isthmus. The adnexa, liver and retroperitoneum were normal; chorionic gonadotrophin hormone beta fraction (β-hGC) was found to be 225,000 mIU/mL. Given the clinical diagnosis of isthmic-cervical pregnancy, satisfied parity with a history of salpingoclasia and probable choriocarcinoma, a simple abdominal hysterectomy was performed without complications. She received chemotherapy with methotrexate and etoposide for 8 weeks. At the conclusion of the chemotherapy scheme the β-hGC was found to be: 1.28 mIUI/mL.
Conclusions: Cervical choriocarcinoma is rare; its location endangers the life of patients due to the high risk of hemorrhage, despite having good prognosis and adequate response to chemotherapy.


REFERENCES

  1. Mouhajer M, Obed S, Okpala AM. Cervical ectopic pregnancy in resource deprived areas: A rare and difficult diagnosis. Ghana Med J. 2017; 51 (2): 94-97. doi.10.4314/gmj.v51i2.8.

  2. Slobodanka LJ, Arsenijevic PS, Kljakic D, Djuric JM, Milosavljevic MZ, Protrka ZM, et al. Gestational choriocarcinoma of the cervix. Arch Iran Med. 2014; 17 (11): 783-5. 84908387709.

  3. Saito M, Azuma T, Nakamura K. On ectopic choriocarcinoma. World Obs Gynecol. 1965; 17 (17): 459-84.

  4. Malek-mellouli M, Ben Amara F, Driss M RH. Cervical trophoblastic tumor: a rare etiology of massive genital hemorrhage. Tunis Med. 2013; 91 (11): 668-9. PMID.24343491.

  5. Takeda K, Mackay J, Watts S. Successful management of cervical ectopic pregnancy with bilateral uterine artery embolization and methotrexate. Case Rep Emerg Med. 2018; 1-4. doi.10.1155/2018/9593824.

  6. DeVita VT, Lawrence TS, Rosenberg SA, DeVita, Hellman, and Rosenberg’s. Cancer: Principles & Practice of Oncology. 10th ed. Philadelphia: Wolters Kluwer, 2015.

  7. Osada H, Teramoto S, Kaijima H, Segawa T, Miyauchi O, Nagaishi M, et al. A novel treatment for cervical and cesarean section scar pregnancies by transvaginal injection of absolute ethanol to trophoblasts: Efficacy in 19 cases. J Minim Invasive Gynecol. 2019; 26 (1): 129-34. https://doi. org/10.1016/j.jmig.2018.04.021

  8. Sorbi F, Sisti G, Pieralli A, Di Tommaso M, Livi L, Buccoliero AM, et al. Cervicoisthmic choriocarcinoma mimicking cesarean section scar ectopic pregnancy. J Res Med Sci. 2013; 18 (10): 914-17. PMID: 24497867.

  9. Agustín A, Savirón R, Lerma D, Herrero A, Campillos J. Coriocarcinoma postgestacional. Rev Chil Obs Ginecol. 2015; 80 (5): 405-11. http://dx.doi.org/10.4067/S0717- 75262015000500009.

  10. Hosni MM, Herath RP, Rashid M. Diagnostic and therapeutic dilemmas of cervical ectopic pregnancy. Obstet Gynecol Surv. 2014; 69 (5): 261-76. doi. 10.1097/ OGX.0000000000000062.

  11. Braaten K, Dutton C. Overview of female permanent contraception. UpToDate. https://www.uptodate. com/contents/overview-of-female-permanentcontraception.

  12. Fox H. Gestational trophoblastic disease: Neoplasia or pregnancy failure? BMJ. 1997; 314: 1363. doi. 10.1136/ bmj.314.7091.1363.

  13. Kalhor N, Ramirez PT, Deavers MT, Malpica A, Silva EG. Immunohistochemical studies of trophoblastic tumors. Am J Surg Pathol. 2009; 33 (4): 633-8. doi. 10.1097/ PAS.0b013e318191f2eb.

  14. Hassadia A, Gillespie A, Tidy J, Everard Rgn J, Wells M, Coleman R, et al. Placental site trophoblastic tumour: Clinical features and management. Gynecol Oncol. 2005; 99 (3): 603-7. doi. 10.1016/j.ygyno.2005.06.054.

  15. Speroff L, Fritz M. Clinical gynecologic endocrinology and infertility. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2005.




2020     |     www.medigraphic.com